AMAZENTIS
17.5.2022 17:06:07 CEST | Business Wire | Press release
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.
This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.
Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.
- Two measures of skeletal muscle strength were improved in the supplemented groups compared to the placebo group. Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%). Muscle strength during knee flexion was also significantly improved at both 500mg (+10.6%) and 1,000mg doses (+10.5%)
- Clinically meaningful improvements on aerobic endurance (+ 10% in peak oxygen consumption [VO2]), physical performance (+ 33 meters on the 6 min walk test), and power output (+5%) were observed in the 1,000mg group, though not statistically significant
- The blood tests and biopsies showed a significant improvement in biomarkers of healthy mitochondrial function and reduced inflammation
“These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine,” explained Johan Auwerx, MD, PhD, co-author and Professor at the Swiss Federal Institute of Technology EPFL.
This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.
“This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products,” said Chris Rinsch, CEO and Co-Founder of Amazentis. “We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer”.
In addition, Amazentis also announced that Dr. Eric Verdin has joined the Amazentis scientific advisory board. Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging and he has dedicated his career to studying longevity with the goal of transforming everyone into healthy centenarians.
“Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.” said. Dr. Eric Verdin.
Doi: 10.1016/j.xcrm.2022.100633
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® Nutrition is brought to you by the inventors of Mitopure™. This novel, science-first brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.timelinenutrition.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
